David A. Rizzieri, MD
Dr. David Rizzieri has focused his clinical/translational research efforts on the care and treatment of patients with leukemia or lymphoma. He is a designated ‘Scholar in Clinical Research’ by the Leukemia and Lymphoma Society and is chair, co-chair or correlative science chair of various CALGB trials involving those with Burkitt’s, MDS, or follicular lymphoma. He has designed novel approaches for non-myeloablative allogeneic therapy to optimize a less toxic regimen for transplant of patients using haplo-identical donors, followed by immune modulating strategies to improve outcomes. In addition, he has led the development of new targeted therapies including anti-stromal directed therapy in lymphoma using a radiolabeled monoclonal antibody to tenascin, anti CD123 directed therapy in leukemia, and various pathway inhibitors. While developing his research program, he has led the growth of clinical/translational research in this field at Duke University and directs the institution's efforts to coordinate studies in this field to promote novel therapies for patients with these illnesses.